Contraindicated in:
Use Cautiously in:
CV: edema.
Derm: pruritus, palmar desquamation, photosensitivity, skin infections, STEVENS-JOHNSON SYNDROME (SJS), thinning of hair, TOXIC EPIDERMAL NECROLYSIS (TEN).
EENT: conjunctivitis, epistaxis, ↓ night vision, blurred vision, contact lens intolerance, corneal opacities, dry eyes.
Endo: hyperglycemia.
F and E: ↑ thirst.
GI: cheilitis, dry mouth, nausea, vomiting, abdominal pain, anorexia, hepatitis, pancreatitis.
Hemat: anemia.
Metab: ↓ high-density lipoprotein cholesterol (HDL-C), hypercholesterolemia, hypertriglyceridemia, ↑ appetite, hyperuricemia.
MS: arthralgia, back pain, muscle/bone pain (↑ in adolescents), hyperostosis.
Neuro: behavior changes, depression, PSEUDOTUMOR CEREBRI, psychosis, SUICIDAL THOUGHTS/BEHAVIORS.
Drug-Drug:
Drug-Food:
(Generic available)
Absorption: Rapidly absorbed following (23–25%) oral administration (bioavailability of Absorica LD higher than that of Absorica); absorption ↑ when taken with a high-fat meal.
Distribution: Appears to be widely distributed.
Protein Binding: 99.9%.
Metabolism/Excretion: Metabolized by the liver and excreted in the urine and feces.
Half-life: 10–20 hr.
NDC Code*
